AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Preliminary results of transdermal oxybutynin phase IIIb trial appear positive.(Brief Article)
2002 APR 18 - (NewsRx.com & NewsRx.net) -- Watson Pharmaceuticals, Inc., (WPI) announced positive preliminary results of a phase IIIb clinical study evaluating its transdermal oxybutynin product, the leading oral medication for overactive bladder, Detrol LA (tolterodine tartrate) and placebo.
The multicenter, placebo-controlled, double-blind, double-dummy clinical study involved 361 patients in 48 centers. Patients were randomized into 3 parallel treatment arms and treated for a period of 12 weeks with either 3.9mg/day transdermal oxybutynin twice weekly, oral 4mg Detrol LA daily, or placebo. All patients were required to have achieved a beneficial response to prior pharmacological treatment for overactive bladder for a minimum of 6 weeks to be eligible for the trial. Most patients had received either tolterodine or oxybutynin, with a median duration of greater than 1 year.
Preliminary results from this clinical study showed that patients treated with transdermal oxybutynin or Detrol LA experienced significant reductions in incontinent episodes as compared with placebo. Daily urinary incontinent episodes decreased by 42% in the placebo group as compared with 62% in the transdermal oxybutynin group and ...
- Preliminary results of transdermal oxybutynin phase IIIb trial appear positive.
- Newspaper article from: Drug Week April 19, 2002 700+ words
...3.9mg/day transdermal oxybutynin twice weekly, oral 4mg Detrol LA daily, or placebo...treated with transdermal oxybutynin or Detrol LA experienced significant...values. Both transdermal oxybutynin and Detrol LA were well tolerated...
- DETROL LA Combined With Standard Treatment for Enlarged Prostate is Twice as...
- Press release article from: PR Newswire November 4, 2004 700+ words
...obstruction first, and adding a therapy like DETROL LA only if the man continues to suffer for...patients with no symptomatic improvement, DETROL LA was added for an additional three months...ejaculation. The most common side effect of DETROL LA was dry mouth. [1,p.3] There was...
- Study shows DETROL LA effectively treats overactive bladder symptoms.
- Newspaper article from: Biotech Week September 22, 2004 700+ words
...for overactive bladder symptoms from DETROL LA (tolterodine tartrate extended release...Urology. This is the first study of DETROL LA in women with mixed incontinence, the...this study, first-line treatment with DETROL LA significantly improved patients' overactive...
- Long-Term Data Show Benefit of DETROL LA as First-Line Therapy for Overactive...
- Press release article from: PR Newswire December 13, 2004 700+ words
...extended release capsules) indicating that DETROL LA significantly reduces symptoms of overactive...people with OAB because it shows that DETROL LA can significantly reduce symptoms with...March 2003, in the 100 countries where DETROL LA is approved for use. In 26 clinical...
- Watson Pharmaceuticals Announces Preliminary Results of Transdermal Oxybutynin...
- Press release article from: PR Newswire February 12, 2002 700+ words
...3B clinical study evaluating its transdermal oxybutynin product, the leading oral medication...Pharmaceuticals' new drug application for transdermal oxybutynin is currently under review at the...weeks with either 3.9 mg/day transdermal oxybutynin twice weekly, oral 4 mg Detrol...
- Transdermal Oxybutynin Significantly Reduces Symptoms.
- Newspaper article from: Drug Week November 23, 2001 700+ words
...clinical trial, patients treated with transdermal oxybutynin (Oxytrol) achieved statistically...United States, was conducted by the Transdermal Oxybutynin Study Group, and reported by G...about 61 years. The 3.9 mg/day transdermal oxybutynin group had significantly greater...
- Transdermal Oxybutynin reduces overactive bladder symptoms with low side...
- Magazine article from: Urologic Nursing June 1, 2002 700+ words
...Researcher, patients treated with transdermal oxybutynin (Oxytrol[TM] achieved statistically...United States, was conducted by the Transdermal Oxybutynin Study Group headed by G. Willy...side effects in the 3.9 mg/day transdermal oxybutynin group and the placebo group, while...
- Transdermal Oxybutynin Significantly Reduces Symptoms.(Brief...
- Newspaper article from: Health & Medicine Week November 26, 2001 700+ words
...clinical trial, patients treated with transdermal oxybutynin (Oxytrol) achieved statistically...United States, was conducted by the Transdermal Oxybutynin Study Group, and reported by G...about 61 years. The 3.9 mg/day transdermal oxybutynin group had significantly greater...
